Narayan Agrawal, MD
Nephrology · Fresh Meadows, NYNPI 1568438570
Payments from drug & device makers
Across 684 payments — averaging $245.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$54K
- Aurinia Pharma U.S., Inc.$36K
- AstraZeneca$25K
- Boehringer Ingelheim$19K
- Lilly USA, LLC$12K
- Vifor Pharma, Inc.$9K
- plus $11K from 29 others
What the payments were for
- Consulting fees$6,1504%
- Speaking & faculty fees$133,16079%
- Travel & lodging$6,3324%
- Food & beverage$22,41913%
- Education$1230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 94 | $54,366 |
| Aurinia Pharma U.S., Inc. | 56 | $35,971 |
| AstraZeneca | 110 | $25,399 |
| Boehringer Ingelheim | 39 | $19,217 |
| Lilly USA, LLC | 20 | $12,379 |
| Vifor Pharma, Inc. | 79 | $9,436 |
| GSK | 9 | $3,414 |
| Akebia Therapeutics Inc | 29 | $1,118 |
| Amgen(2 entities) | 37 | $1,032 |
| Calliditas Therapeutics US Inc. | 31 | $816 |
| Bayer | 28 | $732 |
| Mallinckrodt Hospital Products Inc. | 12 | $609 |
| Otsuka America Pharmaceutical, Inc. | 24 | $565 |
| Novartis | 17 | $445 |
| Fresenius USA Marketing, Inc. | 19 | $395 |
| Novo Nordisk | 9 | $387 |
| ANI Pharmaceuticals, Inc. | 12 | $288 |
| Scpharmaceuticals Inc. | 6 | $276 |
| Fresenius USA Manufacturing, Inc. | 11 | $266 |
| OPKO Pharmaceuticals, LLC | 9 | $193 |
| Ardelyx, Inc. | 6 | $147 |
| Johnson & Johnson | 1 | $125 |
| Mallinckrodt Enterprises LLC | 4 | $86 |
| Merck | 1 | $75 |
| Shield Therapeutics Inc | 4 | $70 |
| Renalytix AI, Inc. | 3 | $67 |
| Daiichi Sankyo Inc. | 3 | $65 |
| Ultragenyx Pharmaceutical Inc. | 3 | $59 |
| Sanofi | 2 | $48 |
| Mannkind Corporation | 1 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Blue Earth Diagnostics | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Rockwell Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$168,183 in reported general payments places this provider in the 90th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 127 | $243,903 |
| FarxigaDapagliflozin Propanediol | 184 | $216,511 |
| JardianceEmpagliflozin | 168 | $198,844 |
| KerendiaFinerenone | 134 | $163,374 |
| LokelmaSodium Zirconium Cyclosilicate | 133 | $145,244 |
| VelphoroSucroferric Oxyhydroxide | 29 | $89,217 |
| Sevelamer Carbonate | 189 | $44,280 |
| ProsolParenteral Amino Acid 20% No.1 | 164 | $28,303 |
| AuryxiaFerric Citrate | 12 | $24,987 |
| ProcritEpoetin Alfa | 23 | $23,289 |
| Calcium Acetate | 206 | $16,013 |
| DapagliflozinDapagliflozin Propanediol | 15 | $12,043 |
| RenvelaSevelamer Carbonate | 12 | $11,967 |
| AranespDarbepoetin Alfa In Polysorbat | 14 | $5,010 |
| Nifedipine ErNifedipine | 117 | $3,963 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $25,399 | $361,755317 claims |
| Boehringer IngelheimJardiance | $19,217 | $198,844168 claims |
| BayerKerendia | $732 | $163,374134 claims |
| Fresenius USA Marketing, Inc.Velphoro | $395 | $89,21729 claims |
| Akebia Therapeutics IncAuryxia | $1,118 | $24,98712 claims |
| Johnson & JohnsonProcrit | $125 | $23,28923 claims |
| AmgenAranesp | $1,032 | $5,01014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 nephrology providers in New York.
Other nephrology in Fresh Meadows
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Robert LynnBronx$2M
- Jodumutt BhatMaspeth$1.5M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
- Frank CortazarAlbany$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.